Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union’s In ...

According to a regulatory filing on Friday, the combined agreements provide Tempus with $192.5 million in total cash commitments over five years, consisting of $137.5 million directly from Bristol ...

Tempus AI sits at the intersection of AI infra and clinical diagnostics. It's a holding in both the ROBO Global Artificial ...

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction.

On October 23, 2026, Tempus AI announced a series of agreements with Bristol-Myers Squibb and Pathos AI that significantly expand the use of Tempus’s de-identified multimodal real-world data and ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Tempus AI (TEM) reports results for the ...

Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, "BMS") and ...

(NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS ...

Oct 23 (Reuters) - Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to ...

"We believe this transaction represents an exciting next chapter for Personalis," the company's Chief Executive Chris Hall, said in a written statement. "Combining with Tempus gives us the scale, ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing ...